Trials start on new bipolar disorder drug

A NEW drug to control bipolar disorder has been identified by Oxford University researchers in a study of mice.

The drug is similar to lithium, the most common treatment, but without its side-effects, which include weight gain and kidney damage in long-term use.

The newly-identified drug, called ebselen, is known to be safe in humans, and its use for bipolar disorder, which causes severe depression and mood swings, can now be tested in clinical trials.

Dr Grant Churchill, of the department of pharmacology at Oxford University, said: “Lithium has been used for over 60 years and remains the most effective treatment for bipolar disorder, but suffers from toxicity and has many side-effects.

“Ebselen is an experimental drug that has been tested in people for other conditions, and does not have problematic side-effects like lithium does.

“We urgently need to test if ebselen works like lithium in people.”

The work was funded by the UK Biotechnology and Biological Sciences Research Council, and the findings have been reported in the journal Nature Communications.

Bipolar disorder is estimated to affect about one person in every 100 in the UK.

Related links

Comments(3)

Grunden Skip says...
1:37am Sat 12 Jan 13

I went to my doctor because I couldn't make up my mind what I liked best, Coke or Diet Coke, he told me not to worry, I was just Bi-Cola.

Cherwell says...
1:17pm Sat 12 Jan 13

This drug is not at all similar to lithium ! Lithium is simply a chemical element, and so the drug actually taken is lithium carbonate which is an inorganic salt similar to sodium carbonate or potassium carbonate. But ebselen is a complex organic molecule, 2-Phenyl-1,2-benzose
lenazol-3-one .

You might as well say that sugar is similar to aspartame . It isn't.

Cherwell says...
1:26pm Sat 12 Jan 13

Aspartame is
N-(L-α-Aspartyl)-L-
phenylalanine 1-methyl ester .

Sugar is also an organic molecule, but a completely different one.

click2find

About cookies

We want you to enjoy your visit to our website. That's why we use cookies to enhance your experience. By staying on our website you agree to our use of cookies. Find out more about the cookies we use.

I agree